In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Are Incentives Out Of Balance With Patient Need?

Executive Summary

Incentives matter; they motivate us to do things. There is renewed interest in just what motivates the life sciences industry to make the choices it does when determining the diseases it will focus on, and how much effort it puts in. This stems from concern about too much effort going into some areas, and too little in others.

You may also be interested in...



Bluebird Bio Decision in Europe Is A Wake-Up Call For Payers and Industry

Bluebird bio’s decision to focus on the US market is being seen as a broader signal of the need for changes in market access policies to enable gene therapies to be made available for European patients. Only collaborative work will create solutions acceptable to payers and companies, and finding an acceptable price that both can live with will be crucial.

Flexibility Is Key To Making England’s Innovative Medicines Fund Work

Stakeholders are calling for NHS England and NHS Improvement (NHSE&I) and the health technology assessment body NICE to bring more flexibility into England’s new Innovative Medicines Fund, which is due for launch later in 2021.

Expectations Are High But What Precisely Will England’s New IMF Deliver?

The Innovative Medicines Fund, due for launch in England later this year, may provide industry with an opportunity to hold key public bodies to account.

Topics

UsernamePublicRestriction

Register

IV124454

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel